Subscribe
12 June 2025NewsAmericasMuireann Bolger

Vidal: Coke Morgan Stewart's rulings are 'taxing innovation'

Two decisions by acting USPTO director Coke Morgan Stewart have “damaging” consequences, warns Vidal | Stewart kickstarts campaign of implied criticism of predecessor’s record.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
USPTO’s Stewart: Don’t nix patents as penalty for misconduct
10 June 2025   Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio.
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025   As the US legal sector comes under political pressure for its inclusion efforts, LSIPR's sister magazine reveals its Top 100 for 2025, highlighting the individuals fighting to keep progress at the heart of IP.
Careers
Acting USPTO director sworn in moments after Trump takes office
23 January 2025   ‘Distinguished’ litigator Coke Morgan Stewart takes her place as deputy and interim director of the US Patent and Trademark Office, where she was formerly employed for a decade.


Editor's picks

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

Editor's picks

Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths
Former pharma GC brings in-house perspective to McGuireWoods
Sandoz eyes US biosimilar launch as Regeneron settles
Killing the golden goose of US drug innovation (Part I): Follow the money
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders